Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Vir Biotechnology, Inc.’s VIR share price has dipped by 5.45%, which has investors questioning if this is right time to buy.

5 analysts have expressed a variety of opinions on Vir Biotechnology (NASDAQ:VIR) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Net Cash Consumed: $75.6 million in Q1 2025. Vir Biotechnology Inc (NASDAQ:VIR) successfully initiated the ECLIPSE Phase III registrational program for hepatitis delta virus, marking a significant ...

Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a devastating disease with no ...